Cargando…
Successful treatment of enterovirus-infected mice by 2-(alpha- hydroxybenzyl)-benzimidazole and guanidine
Echo virus 9- or Coxsackie A 9-infected newborn mice are protected from paralysis and death by combined treatment with nontoxic concentrations of HBB plus guanidine. HBB alone also protects Coxsackie A 9, but not echo virus 9-infected animals, whereas guanidine alone is ineffective in either case. P...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1976
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2190224/ https://www.ncbi.nlm.nih.gov/pubmed/1271013 |
_version_ | 1782146779049885696 |
---|---|
collection | PubMed |
description | Echo virus 9- or Coxsackie A 9-infected newborn mice are protected from paralysis and death by combined treatment with nontoxic concentrations of HBB plus guanidine. HBB alone also protects Coxsackie A 9, but not echo virus 9-infected animals, whereas guanidine alone is ineffective in either case. Protection is due to inhibition of virus multiplication via the antiviral activity of these selective inhibitors. Treatment must be begun at the latest 48 h after virus inoculation. 3 days of treatment are sufficient if started at the time of virus inoculation. Failure of protection after treatment with one compound alone is not due to rapid development of drug-resistant virus mutants. Infected, successfully treated mice may develop a solid immunity. |
format | Text |
id | pubmed-2190224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1976 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-21902242008-04-17 Successful treatment of enterovirus-infected mice by 2-(alpha- hydroxybenzyl)-benzimidazole and guanidine J Exp Med Articles Echo virus 9- or Coxsackie A 9-infected newborn mice are protected from paralysis and death by combined treatment with nontoxic concentrations of HBB plus guanidine. HBB alone also protects Coxsackie A 9, but not echo virus 9-infected animals, whereas guanidine alone is ineffective in either case. Protection is due to inhibition of virus multiplication via the antiviral activity of these selective inhibitors. Treatment must be begun at the latest 48 h after virus inoculation. 3 days of treatment are sufficient if started at the time of virus inoculation. Failure of protection after treatment with one compound alone is not due to rapid development of drug-resistant virus mutants. Infected, successfully treated mice may develop a solid immunity. The Rockefeller University Press 1976-06-01 /pmc/articles/PMC2190224/ /pubmed/1271013 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Articles Successful treatment of enterovirus-infected mice by 2-(alpha- hydroxybenzyl)-benzimidazole and guanidine |
title | Successful treatment of enterovirus-infected mice by 2-(alpha- hydroxybenzyl)-benzimidazole and guanidine |
title_full | Successful treatment of enterovirus-infected mice by 2-(alpha- hydroxybenzyl)-benzimidazole and guanidine |
title_fullStr | Successful treatment of enterovirus-infected mice by 2-(alpha- hydroxybenzyl)-benzimidazole and guanidine |
title_full_unstemmed | Successful treatment of enterovirus-infected mice by 2-(alpha- hydroxybenzyl)-benzimidazole and guanidine |
title_short | Successful treatment of enterovirus-infected mice by 2-(alpha- hydroxybenzyl)-benzimidazole and guanidine |
title_sort | successful treatment of enterovirus-infected mice by 2-(alpha- hydroxybenzyl)-benzimidazole and guanidine |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2190224/ https://www.ncbi.nlm.nih.gov/pubmed/1271013 |